Continuous bromocriptine therapy in menstrual migraine

Neurology

Volumn 48, Issue 1, 1997, Pages 101-102

  Herzog, Andrew G ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG USE; FEMALE; HUMAN; MENSTRUAL CYCLE; MIGRAINE; PRIORITY JOURNAL;

EID: 0031033825     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.48.1.101     Document Type: Article

References (18)

1. Silberstein S, Merriam GR. Estrogens, progestins, and headache. Neurology 1991;41:786-793.
2. Nattero G. Menstrual headache. In: Critchley M, ed. Advances in neurology. New York: Raven Press, 1982:215-226.
3. Herrmann WM, Horowski R, Dannehl K, Kramer U, Lurati K. Clinical effectiveness of lisuride hydrogen maleate: a double-blind trial versus methysergide. Headache 1977;17:54-60.
4. Somerville BW, Herrmann WM. Migraine prophylaxis with lisuride hydrogen maleate: a double-blind study of lisuride versus placebo. Headache 1978;18:75-79.
5. Andersch B, Hahn L, Wendestam C, Ohman R, Abrahamsson L. Treatment of premenstrual syndrome with bromocriptine. Acta Endocrinol 1978;88(suppl 216):165-174.
6. Ylostalo P, Kauppila A, Puolakka J, Ronnberg L, Janne O. Bromocriptine and norethisterone in the treatment of premenstrual syndrome. Obstet Gynecol 1982;58:292-298.
7. Andersen AN, Larsen JF, Steenstrup OR, Svendstrup B, Nielsen J. Effect of bromocriptine on the premenstrual syndrome: a double-blind clinical trial. Br J Obstet Gynaecol 1977;84:370-374.
8. Hockaday JM, Peet KM, Hockaday TD. Bromocriptine in migraine. Headache 1976;16:109-114.
9. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia 1988;8(suppl 7):1-96.
10. Moskowitz MA. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 1993;43:816-820.
11. MacLennan SJ, Martin GR. Actions of non-peptide ergot alkaloids at 5-HT1-like and 5-HT2 receptors mediating vascular smooth muscle contraction. Arch Pharmacol 1990;342:120-129.
12. Beart PM, McDonald D, Cincotta M, DeVries DJ, Gundlach AL. Selectivity of some ergot derivatives for 5-HT1 and 5-HT2 receptors of rat cerebral cortex. Gen Pharmacol 1986;17:57-62.
13. Peroutka SJ, Havlik S, Oksenberg D. Antimigraine drug interactions with cloned human 5-hydroxytryptamine receptor subtypes. Headache 1993;33:347-350.
14. Murialdo G, Martignoni E, DeMaria A, et al. Changes in the dopaminergic control of prolactin secretion and in ovarian steroids in migraine. Cephalalgia 1986;6:43-49.
15. Herzog AG, Seibel MM, Schomer DL, Vaitukaitis JL, Geschwind N. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 1986;43: 341-346.
16. Somerville BW. The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology 1972;22:355-365.
17. Hammarback S, Damber J-E, Backstrom T. Relationship between symptom severity and hormone changes in women with premenstrual syndrome. J Clin Endocrinol Metab 1989;68: 125-130.
18. Power RF, Mani SK, Codina J, Conneely OM, O'Malley BW. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 1991;254:1636-1639.